Literature DB >> 11576286

Restricted surgical management of vulvar intraepithelial neoplasia 3: Focus on exclusion of invasion and on relief of symptoms.

M. van Beurden1, N. van Der Vange, F. J. W. ten Kate, A. J. M. de Craen, M. S. Schilthuis, F. B. Lammes.   

Abstract

van Beurden M, van der Vange N, ten Kate FJW, de Craen AJM, Schilthuis MS, Lammes FB. Restricted surgical management of vulvar intraepithelial neoplasia 3: Focus on exclusion of invasion and on relief of symptoms. Int J Gynecol Cancer 1998; 8: 73-77. A study was undertaken to determine the effectiveness of extensive and restricted surgery for vulvar intraepithelial neoplasia (VIN) 3. All consecutive patients with VIN 3 admitted to a tertiary referral hospital were included. The main outcome measures were relief and recurrence of symptoms and progression to invasive disease in patients with VIN 3 after extensive or restricted surgery. Of every vulvoscopic visible lesion a biopsy was taken to establish extent and grade of VIN and to rule out invasive carcinoma. Patients with unifocal VIN 3 underwent extensive surgery. Patients with multifocal VIN 3 underwent extensive or restricted surgery or an expectant management was adopted, depending on the existence of symptoms and the presence of invasive vulvar carcinoma. Forty-seven patients were evaluated. Eighty-three percent of patients had a long history of symptoms. Eight patients (17%) had unifocal VIN 3. In 9% of the patients a superficially invasive vulvar carcinoma was found, ie with a depth of invasion of 1 mm or less. Only 20% of the extensively operated patients had free surgical margins. There was recurrence of symptoms in all of the extensively operated patients, in contrast to a 26% persistence or recurrence rate of symptoms in the restrictedly operated patients. In patients with multifocal VIN 3 who underwent restricted surgery, young age of the patient (P = 0.02) and large extension of VIN 3 (P = 0.02) were significant factors in predicting persistence or recurrence of symptoms. Only once was a superficially invasive vulvar carcinoma diagnosed during follow-up, and this was in an extensively operated patient. Vulvoscopically directed biopsies in VIN 3 are a safe method to exclude invasive disease. Restricted surgery is effective in relieving symptoms in multifocal VIN 3.

Entities:  

Year:  1998        PMID: 11576286     DOI: 10.1046/j.1525-1438.1998.09733.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Vulval Intraepithelial Neoplasia 3: A Clinico-Pathological Review in a Tertiary Care Centre Over 10 Years.

Authors:  Karthik C Bassetty; Anitha Thomas; Rachel G Chandy; Dhanya S Thomas; Vinotha Thomas; Abraham Peedicayil; Ajit Sebastian
Journal:  J Obstet Gynaecol India       Date:  2022-04-06

2.  Vulvar Intraepithelial Neoplasia 3 in Women Less Than 35 Years.

Authors:  Joshua P Kesterson; Shashikant Lele
Journal:  J Low Genit Tract Dis       Date:  2009-10       Impact factor: 1.925

Review 3.  Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.

Authors:  Theresa A Lawrie; Andy Nordin; Manas Chakrabarti; Andrew Bryant; Sonali Kaushik; Litha Pepas
Journal:  Cochrane Database Syst Rev       Date:  2016-01-05

4.  Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia.

Authors:  E J Davidson; L S Morris; I S Scott; S M Rushbrook; K Bird; R A Laskey; G E Wilson; H C Kitchener; N Coleman; P L Stern
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

5.  Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy.

Authors:  Mario Preti; Lauro Bucchi; Bruno Ghiringhello; Silvana Privitera; Valentina Frau; Elisabetta Corvetto; Chiara Benedetto; Leonardo Micheletti
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.